March 10 (Reuters) – Gerresheimer on Tuesday further deferred the release of 2025 financial statements to June, citing probes into its business deals, a delay that is now set to cost the German medical products maker its spot on Deutsche Boerse’s SDAX index.
The Duesseldorf-based company said the statements were delayed due to the ongoing investigations by an external auditing firm into business transactions in 2024 and 2025 and the longer time needed to prepare the documents required for the audit.
Gerresheimer was originally expected to release the results on February 26 but delayed them. While the company did not give any deadline then, it said on Tuesday that the audited annual and consolidated financial statements for 2025 would not be published by March 31. Its board now aims to publish them in June.
Gerresheimer also said it would delay the release of its first-quarter results, previously scheduled for April 16, and would announce a new date soon.
The delays prompted the company to postpone its annual general meeting, which was originally scheduled for June 3.
Earlier in the day, Germany’s financial watchdog BaFin said it has initiated an audit of Gerresheimer’s interim financial statements dated from December 1, 2024 to May 31, 2025, and expanded ad hoc audits of statements as of November 30, 2024, citing “concrete evidence” of accounting violations.
Gerresheimer has suffered a sharp drop in its share price, a weakening financial outlook, and significant leadership disruptions as the accounting issues unfold.
Its shares have fallen about 28% so far this year, after a 61% slide in 2025.
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Shilpi Majumdar)
